Toyota, Hyundai and Chinese automakers expected to be most impacted by Iran war

Toyota, Hyundai and Chinese automakers expected to be most impacted by Iran war


Toyota Motor Corp. vehicles bound for shipment at the Port of Nagoya in Tokai, Aichi Prefecture, Japan, on Tuesday, April 29, 2025.

Toru Hanai | Bloomberg | Getty Images

DETROIT — Toyota Motor, Hyundai Motor and Chinese automakers such as Chery face the most potential impact of non-domestic automakers from the U.S.-Israel war with Iran, according to an analysis by Bernstein.

Those international automakers account for roughly a third of sales in the Middle East, according to the report, led by Toyota at 17%, Hyundai at 10% and Chery at 5%. In Iran specifically, Bernstein reports Iranian automakers Iran Khodro and SAIPA lead, followed by Chery with a 6% market share.

Other Chinese carmakers also are expected to be impacted, as the Middle East has become a growing destination for Chinese auto exports. Bernstein, citing China export data, said the region accounted for about 17% of China’s passenger vehicle exports in 2025.

The Bernstein report notes that while sales in the region will be impacted, the closing of the Strait of Hormuz, which links the Persian Gulf to the Gulf of Oman and the Indian Ocean, and rising oil prices will have ripple effects across the global automotive industry.

“Closure of the Strait of Hormuz adds 10-14 days to transit times,” Bernstein analyst Eunice Lee said in a Wednesday investor note, adding “a prolonged conflict and closure of the strait would hurt sales, increase logistics costs, and delay deliveries.”

Julian Emanuel: Gasoline near $4 a gallon becomes an economic tipping point

Roughly 20 million barrels of crude oil travel through the strait every day, according to consulting firm AlixPartners. It’s also a “critical passage” for vehicle and parts shipments to the Middle East, Bernstein noted.

Bernstein said any effect on Japanese automakers “appears limited for now, but close monitoring of developments is still required.” It also said, of the European automakers, Chrysler and Jeep parent Stellantis “seems to have the largest exposure in light of its overall issues.”

“The impact of rising gasoline pump prices is already being seen in Stellantis’ 11% stock price slump since its close last Friday – making so sharp a pivot to gas guzzling HEMI V8 engines and writing off its electrification efforts seems particularly inauspiciously timed at the moment,” Lee wrote.

U.S. crude oil prices on Thursday topped $80 per barrel, and retail gasoline prices in the U.S. have jumped nearly 27 cents since last week to $3.25 per gallon on average, according to the motorist group AAA.

Stellantis this week said it is “closely monitoring developments across the affected countries,” noting it’s “not yet possible to fully assess the potential impact on local operations.”

Toyota, Hyundai and Chery did not immediately respond for requests for comment.



Source

Inside the booming business of wellness third spaces and membership clubs
Business

Inside the booming business of wellness third spaces and membership clubs

A few years ago, Grace Guo began to crave places in New York City where hanging out with friends didn’t have to involve alcohol. Newly sober and surrounded by friends who also chose not to drink, Guo said she wanted alternatives to the typical social scene. After some research, she landed on Bathhouse and Othership: […]

Read More
FDA vaccine head will step down in April after string of controversial decisions
Business

FDA vaccine head will step down in April after string of controversial decisions

The logo for the Food and Drug Administration is seen ahead of a news conference at the Health and Human Services Headquarters in Washington, DC on April 22, 2025. Nathan Posner | Anadolu | Getty Images A key U.S. Food and Drug Administration official who oversees vaccines and biotech treatments will step down from the […]

Read More
FDA reversals leave investors worrying about the fates of other experimental drugs
Business

FDA reversals leave investors worrying about the fates of other experimental drugs

Investors are concerned about the fates of multiple experimental drugs for hard-to-treat diseases following a string of recent rejections from the U.S. Food and Drug Administration.  The FDA in the past year has denied or discouraged the applications of at least eight drugs, according to RTW Investments, including a gene therapy for Huntington’s disease from […]

Read More